Tofacitinib for moderate–severe UC

Feb 6, 2018 - E-Mentoring in IBD | Volume 11 • 2018

Issue 03

Clinical Question

Is tofacitinib, a preferential inhibitor of JAK1 and JAK3, effective for inducing and maintaining remission in moderate-to-severe ulcerative colitis (UC)?

Editor’s Bottom Line

Tofacitinib shows good efficacy for induction and maintenance of remission in UC, but also an increased risk of non-serious infection.

References

Sandborn WJ, Su C, Sands BE, et al; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 May 4;376(18):1723–36. http://www.ncbi.nlm.nih.gov/pubmed/28467869

Synopsis

For the OCTAVE Induction trials (1 and 2), eligible patients had moderate–severe UC (Mayo score 6–12 with endoscopic subscore 2–3) and had failed or had adverse events to one of the following: steroids, immunosuppressants, infliximab, or adalimumab. Permitted adjuvant therapies were oral 5-ASA or prednisone (25 mg/d or less) at stable doses during induction. Patients were randomized 4:1 to tofacitinib (10 mg bid) or placebo for 8 weeks. Patients were then invited to participate in the OCTAVE Sustain trial if they had a clinical response defined as a 3-point reduction in baseline Mayo (and 30% overall) and improvement by 1 point in rectal bleeding. Patients were randomized 1:1:1 to tofacitinib twice daily at 5 mg or 10 mg or placebo until week 52. Prednisone was tapered during OCTAVE Sustain. Endoscopy was performed at weeks 0, 8, and 52. Clinical remission was the primary endpoint for both the induction and maintenance studies. Adverse events were monitored throughout.

At weeks 8 and 52, patients receiving tofacitinib had significantly higher rates of remission (Table 1) and mucosal healing. During Sustain at week 52, tofacitinib at the higher dose also increased mucosal healing (37.4% vs. 45.7%) versus placebo (13.1%). Adverse and severe adverse events were similar across the trials except that patients receiving the study drug had more changes in cholesterol profile and more episodes of non-serious infection (including herpes Zoster).

Details

Study Design: 3 prospective, double-blind RCTs
Funding: Pfizer
Allocation: Central randomization was stratified. Induction: treatment history with biologics, steroid use at baseline, and geography. Sustain: induction-trial group assignment and remission status at end of Induction.
Setting: 297 sites worldwide
Level of Evidence: 1b (Oxford Levels of Evidence)

The summary and conclusion in this issue of E-mentoring in IBD pertains to the manuscript(s) being reviewed, and should be considered in the context of what is already known surrounding the topic and incorporated into practice as deemed appropriate by the individual learner.